High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).
The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
The EGFR tyrosine kinase inhibitor (TKI) dacomitinib showed superior overall survival (OS) vs gefitinib in patients with treatment-naïve EGFR-positive non-small-cell lung cancer (NSCLC) in the final analysis of the ARCHER 1050 study.
Adjuvant treatment with a modified FOLFIRINOX (mFOLFIRINOX) regimen extends overall survival (OS) by nearly 20 months compared with standard chemotherapy in patients with nonmetastatic pancreatic ductal adenocarcinoma (PDAC), results of a phase III trial have shown.
Most patients with advanced non-small-cell lung cancer (NSCLC) can have improved overall survival (OS) with first-line pembrolizumab without chemotherapy even if their PD-L1 expression levels are low, results of the phase III KEYNOTE-042 trial have shown.
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).